Evidence map›Paper›PMID 40676316›Full record

ArticleWorld journal of urology2025

PSA density correlates to pathology T stage and ISUP grade: insights from a cohort of 3568 radical prostatectomy cases.

Maxime Pattou, Yann Neuzillet, Tarek Ghoneim, Pierre-Olivier Bosset, Jean-Marie Herve, Victor Vanalderwerelt, Denis Bohin, Pierre-Marie Lugagne, Yanish Soorojebally, Thierry Lebret

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maxime PattouDepartment of Urology, Foch Hospital, University of Paris-Saclay - UVSQ, 40 rue Worth, 92150, Suresnes, France. maxime.pattou@gmail.com.
Yann NeuzilletDepartment of Urology, Foch Hospital, University of Paris-Saclay - UVSQ, 40 rue Worth, 92150, Suresnes, France.
Tarek GhoneimDepartment of Urology, Foch Hospital, University of Paris-Saclay - UVSQ, 40 rue Worth, 92150, Suresnes, France.
Pierre-Olivier BossetDepartment of Urology, Foch Hospital, University of Paris-Saclay - UVSQ, 40 rue Worth, 92150, Suresnes, France.
Jean-Marie HerveDepartment of Urology, Foch Hospital, University of Paris-Saclay - UVSQ, 40 rue Worth, 92150, Suresnes, France.
Victor VanalderwereltDepartment of Urology, Foch Hospital, University of Paris-Saclay - UVSQ, 40 rue Worth, 92150, Suresnes, France.
Denis BohinDepartment of Urology, Foch Hospital, University of Paris-Saclay - UVSQ, 40 rue Worth, 92150, Suresnes, France.
Pierre-Marie LugagneDepartment of Urology, Foch Hospital, University of Paris-Saclay - UVSQ, 40 rue Worth, 92150, Suresnes, France.
Yanish SoorojeballyDepartment of Urology, Foch Hospital, University of Paris-Saclay - UVSQ, 40 rue Worth, 92150, Suresnes, France.
Thierry LebretDepartment of Urology, Foch Hospital, University of Paris-Saclay - UVSQ, 40 rue Worth, 92150, Suresnes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionProstate-specific antigen density (PSAD) is a valuable detection tool for prostate cancer (PCa) with PSA levels in the "gray zone" (4-10 ng/mL). However, its relationship with final pathology outcomes remains limited, especially on large cohorts.

objectiveThis study aimed to describe PSAD distributions according to final pathology findings (pathological T stage and ISUP grade) and identify clinical and pathological factors influencing PSAD variations.

methodsWe analyzed a prospective cohort of 3568 patients who underwent radical prostatectomy for PCa in our center between 2007 and 2025. PSAD was calculated using serum PSA (ng/mL) divided by prostate weight (g) from pathology reports. Associations between PSAD and pathology T stage, ISUP grade, total testosterone, cholesterol levels, and statin use were done using Spearman's correlation coefficient, stratified rank ANCOVA analysis and a multiple linear regression.

resultsThe median PSAD was 0.17 ng/mL/g (IQR: 0.12-0.25). PSAD levels increased gradually with advanced pathology T stage (pT3a and T3b) and higher ISUP grade (p < 0.001 for both). After adjusting for confounding covariates (age and D'Amico risk classification), PSAD remained significantly associated with Pathology T stage and ISUP. Within the high-risk category, high biopsy ISUP and pathology ISUP grades were associated with lower PSAD levels (r = -0.59 and - 0.49 respectively). PSAD levels were associated with four adverse pathology outcomes, namely positive surgical margins, nodal involvement, ISUP ≥ 4 upgrading and pT ≥ 3 upstaging. Multivariate analysis identified higher biopsy ISUP grade and PSA levels as positive predictors of PSAD, while age, BMI, and testosterone were negatively associated.

conclusionPSAD correlates with PCa aggressiveness on pathology, making it a clinically relevant biomarker. Future studies should investigate PSAD's relation with adverse oncological outcomes, including biochemical recurrence.

Indexed as

ProstatectomyProstate-Specific AntigenProstatic NeoplasmsAgedCohort StudiesHumansMaleMiddle AgedNeoplasm GradingNeoplasm StagingProspective StudiesProstate-Specific AntigenBiomarkersISUP gradePathological stagingProstate cancerPSA densityRadical prostatectomyRisk stratification

Identifiers

PMID40676316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.